The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•25 March 2026•

1 min read

Sarepta Therapeutics Reports Positive Early Clinical Data for siRNA Pipeline

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Phase 1/2 results for SRP-1001 and SRP-1003 showed dose-dependent muscle exposure and early biomarker effects.

Version History

4 additional sources confirmed this story

Sarepta Therapeutics (NASDAQ: SRPT) has released the first clinical data from its siRNA pipeline, marking a significant milestone for its neuromuscular disease treatments. The Phase 1/2 results for programs SRP-1001 and SRP-1003 demonstrated dose-dependent muscle exposure and encouraging early biomarker effects. These clinical programs are specifically designed to target facioscapulohumeral muscular dystrophy type 1 (FSHD1) and myotonic dystrophy type 1 (DM1). According to the company, the early studies reported a favorable safety and tolerability profile among the patient population. This data validates Sarepta’s precision genetic medicine platform and provides a foundation for further clinical development. The positive results are expected to bolster investor confidence in the company's long-term pipeline for rare genetic disorders.